Literature DB >> 1974268

Circulating somatostatin after oral glucose in hypothyroidism.

A W Kung1, K S Lam, K K Pun, C Wang, R T Yeung.   

Abstract

The response of circulating somatostatin-like immunoactivity (SLI) to oral glucose and its relation to other pancreatic islet cell hormones were studied in 10 hypothyroid subjects before and after treatment. None of the patients suffered from diabetes mellitus or obesity. Compared with normal controls, the hypothyroid subjects had higher fasting and stimulated SLI levels but lower fasting pancreatic glucagon levels. Integrated glucose and insulin responses following glucose ingestion were normal, but the peak insulin response was delayed to 120 min suggesting impaired pancreatic beta-cell response to oral glucose. On the other hand, the peak response of plasma C-peptide was higher probably because of a reduction in metabolic clearance. In both hypothyroid subjects and controls, a significant correlation was found between the maximal increment of SLI and the maximal decrement of glucagon following oral glucose. In conclusion, plasma SLI is increased in hypothyroidism. The changes in SLI may be due to either an increased hormonal secretion or a reduced metabolic clearance in hypothyroidism. This elevated SLI might contribute to the slower gastrointestinal motility observed in hypothyroidism. Our data also suggest that the reduction in glucagon secretion may be secondary to the increase in circulating SLI.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974268     DOI: 10.1007/BF03350690

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  C-peptide during glucose loading in myxedema.

Authors:  V Felt
Journal:  Horm Metab Res       Date:  1988-06       Impact factor: 2.936

2.  Intestinal disorders in hypothyroidism. Clinical and manometric study.

Authors:  R L Duret; P A Bastenie
Journal:  Am J Dig Dis       Date:  1971-08

3.  Insulin levels in thyrotoxicosis and primary myxoedema: response to intravenous glucose and glucagon.

Authors:  D Andreani; G Menzinger; F Fallucca; G Aliberti; G Tamburrano; C Cassano
Journal:  Diabetologia       Date:  1970-02       Impact factor: 10.122

4.  Influence of gastric emptying-rate and of insulin response on oral glucose tolerance in thyroid disease.

Authors:  C D Holdsworth; G M Besser
Journal:  Lancet       Date:  1968-09-28       Impact factor: 79.321

5.  The effect of thyroid disease on proinsulin and C-peptide levels.

Authors:  S F Beer; J H Parr; R C Temple; C N Hales
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

6.  Insulin secretory response to different secretagogues in hyper- and hypothyroid mice.

Authors:  B Ahrén; I Lundquist
Journal:  Acta Endocrinol (Copenh)       Date:  1981-08

7.  Gastric secretion and emptying in hypothyroidism.

Authors:  A Dubois; J M Goldman
Journal:  Dig Dis Sci       Date:  1984-05       Impact factor: 3.199

8.  Determination of free and total insulin and C-peptide in insulin-treated diabetics.

Authors:  H Kuzuya; P M Blix; D L Horwitz; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

9.  Evidence of a paracrine role for pancreatic somatostatin in vivo.

Authors:  G J Taborsky
Journal:  Am J Physiol       Date:  1983-12

10.  Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction.

Authors:  K Polonsky; J Jaspan; W Pugh; D Cohen; M Schneider; T Schwartz; A R Moossa; H Tager; A H Rubenstein
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more
  2 in total

1.  Elevated circulating somatostatin levels in acromegaly.

Authors:  M Arosio; S Porretti; P Epaminonda; C Giavoli; C Gebbia; C Penati; P Beck-Peccoz; M Peracchi
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

2.  Standard hypothyroid treatment did not restore proper metabolic response to carbohydrate.

Authors:  Agnieszka Kozacz; Gilmara Gomes de Assis; Urszula Sanocka; Andrzej Wojciech Ziemba
Journal:  Endocrine       Date:  2020-05-13       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.